Key result
Higher soluble PD-L1 levels linked to ~36% increased cardiovascular event risk in CAD.
Why the study?
The prognostic significance of soluble PD-L1 on cardiovascular outcomes in patients with coronary artery disease was unknown.
Cohort (n=592)
No
Hazard Ratio: 1.364 (95% CI 1.018–1.828)
Absolute Event Rate: 25% vs 16.9%
p-value: p=0.038
Should not yet change CAD management; hypothesis-generating for soluble PD-L1 as prognostic biomarker.
AIMS: Programmed cell death-1 (PD-1) and its ligand (PD-L1) regulate T cells, leading to immunotolerance. We previously demonstrated that patients with coronary artery disease (CAD) had increased circulating levels of soluble PD-L1 (sPD-L1). However, the prognostic significance of sPD-L1 on cardiovascular outcomes is unknown. In the present study, we evaluated the association between sPD-L1 and cardiovascular events in patients with CAD. METHODS: We prospectively measured sPD-L1 in patients with CAD admitted to Kumamoto University Hospital between December 2017 and January 2020 and observed their cardiovascular event rate. The primary outcome was a composite of death from non-cardiovascular causes, death from cardiovascular causes, non-fatal myocardial infarction, unstable angina pectoris, revascularization, hospitalization for heart failure, and ischemic stroke. RESULTS: , B-type natriuretic peptide, left ventricular ejection fraction, and sPD-L1 were significantly associated with cardiovascular events. Multivariable Cox proportional hazards analysis of factors that were significant in univariate analysis identified that sPD-L1 was significantly and independently associated with cardiovascular events (hazard ratio: 1.364, 95% confidence interval: 1.018-1.828, p=0.038). CONCLUSIONS: Higher sPD-L1 levels were significantly associated with future cardiovascular events in patients with CAD.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2023) conducted a cohort in Coronary Artery Disease (n=592). Higher soluble PD-L1 (sPD-L1) levels vs. Lower sPD-L1 levels was evaluated on Composite of death from non-cardiovascular causes, death from cardiovascular causes, non-fatal myocardial infarction, unstable angina pectoris, revascularization, hospitalization for heart failure, and ischemic stroke (HR 1.364, 95% CI 1.018-1.828, p=0.038). Higher soluble PD-L1 levels were significantly and independently associated with an increased risk of future cardiovascular events in patients with coronary artery disease (HR 1.364).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: